News

Infor-Med has announced the beta release of Praxis Version 5 featuring Datum, a tool that allows physicians to use free text to create, store, and share discrete clinical

GTX Corp and MNX have entered into an exclusive product test agreement to develop a proprietary GPS enabled transport container. Over the following 2 quarters the companies will

ZymoGenetics has initiated phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection (EMERGE study). The first patient

Carefx has announced that Boston Medical Center (BMC) has deployed the Fusionfx Immunization Management portal designed to enter and track H1N1 vaccination administration history and support broad, community-wide

GlaxoSmithKline (GSK) and Genmab have received accelerated approval for Arzerra (ofatumumab) from the FDA for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine

The Food and Drug Administration (FDA) has withdrawn a notice of eligibility and call-for-data for safety and effectiveness regarding Saccharomyces boulardii (S. boulardii). In the original notice published

US Patent and Trademark Office has issued patent to Endocyte covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (US Patent No.

PolyMedix has completed a second clinical study of its anticoagulant reversing agent, PMX-60056. The phase 1B clinical study was a pilot proof-of-concept study conducted in the US under

Alkermes has initiated phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly